The JAK2 V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

Morten Orebo Holmström; Hans Carl Hasselbalch; Mads Hald Andersen

doi:10.1080/2162402X.2017.1358334

The JAK2 V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

Oncoimmunology. 2017 Aug 2;6(11):e1358334. doi: 10.1080/2162402X.2017.1358334. eCollection 2017.

Authors

Morten Orebo Holmström^{1

2}, Hans Carl Hasselbalch¹, Mads Hald Andersen^{2

3}

Affiliations

¹ Department of Hematology, Zealand University Hospital.
² Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital at Herlev.
³ Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Abstract

Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared antigens.

Keywords: CD4 T-cells; Hematological cancer; JAK2; calreticulin; neoantigens.

Publication types

Research Support, Non-U.S. Gov't